临床研究 唑来膦酸治疗老年性骨质疏松的临床观察.PDF

2012;32(9) 南方医科大学学报（J South Med Univ ） ·1287 · 临床研究 唑来膦酸治疗老年性骨质疏松的临床观察 许 翎，邓海鸥，智喜梅，张伟杰，王小娜，吴 文 广东省人民医院老年医学研究所内分泌科，广东 广州 510080 摘要：目的观察唑来膦酸（密固达）在治疗老年性骨质疏松中骨密度与骨代谢指标的变化。方法 对48 例老年性骨质疏松患者 随机分为治疗组23 例，对照组25 例，两组均每日口服维生素D3 与钙尔奇-D ，治疗组加予密固达5 mg 静脉滴注1次，1年后观察 两组骨密度与骨代谢指标的变化。结果 治疗前两组无差异（P0.05）。治疗后，治疗组L 1-4、Neck 、Inter、Wards 骨密度均比对 照组明显增加（P0.05），β-胶原片段（β-CTX）较对照组下降（P0.05），骨钙素（N-MID ）、降钙素（hCT）与对照组相比无明显差异 （P0.05）。结论 静滴1次密固达，1年后能有效地降低骨吸收，提高骨密度，可用于治疗老年性骨质疏松。 关健词：唑来膦酸；老年性骨质疏松 中图分类号：R681 文献标志码：A 文章编号：1673-4254（2012）09-1287-03 doi: 10.3969/j.issn. 1673-4254.2012.09.015 /kcms/detail/44.1627.R1211.028.html Therapeutic effect of zoledronic acid on primary ostsoporosis in elderly patients XU Ling, DENG Haiou, ZHI Ximei, ZHANG Weijie, WANG Xiaona, WU Wen Department of Endocrinology, Instittue of Gerontology, Guangdong General Hospital, Guangzhou 510080, China Abstract: Objective To observe the effect of zoledronic acid on bone mineral density (BMD) and bone metabolic markers in elderly patients with primary osteoporosis. Methods Forty-eight elderly patients with osteoporosis were randomly assigned to zoledronic acid group (n=23) to receive treatment with 5 mg zoledronic acid once a year and the control group (n=25). In both groups, the patients were given Vitamin D3 and caltrate on a daily basis for a year. The bone mineral density (BMD) and bone metabolic markers were observed after the treatment. Results Compared with the control group, zoledronic acid group had significantly higher L1-4, neck, Inter and Wards BMD (P0.05) with reduced B-NTX (P0.05). The N-MID and CT showed no significant differences between the two groups (P0.05). Conclusion Zoledronic acid administration once a year can increase BMD and lower the serum bone turnover metabolism, and can be used in the treatment of primary osteoporosis